These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

145 related items for PubMed ID: 28866093

  • 1. MiR-127 and miR-376a act as tumor suppressors by in vivo targeting of COA1 and PDIA6 in giant cell tumor of bone.
    Herr I, Sähr H, Zhao Z, Yin L, Omlor G, Lehner B, Fellenberg J.
    Cancer Lett; 2017 Nov 28; 409():49-55. PubMed ID: 28866093
    [Abstract] [Full Text] [Related]

  • 2. Restoration of miR-127-3p and miR-376a-3p counteracts the neoplastic phenotype of giant cell tumor of bone derived stromal cells by targeting COA1, GLE1 and PDIA6.
    Fellenberg J, Sähr H, Kunz P, Zhao Z, Liu L, Tichy D, Herr I.
    Cancer Lett; 2016 Feb 01; 371(1):134-41. PubMed ID: 26655997
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5. Expression profiles of miRNAs in giant cell tumor of bone showed miR-187-5p and miR-1323 can regulate biological functions through inhibiting FRS2.
    Jin Y, Zhang J, Zhu H, Fan G, Zhou G.
    Cancer Med; 2020 May 01; 9(9):3163-3173. PubMed ID: 32154662
    [Abstract] [Full Text] [Related]

  • 6. Norcantharidin modulates the miR-30a/Metadherin/AKT signaling axis to suppress proliferation and metastasis of stromal tumor cells in giant cell tumor of bone.
    Chen F, Wang S, Wei Y, Wu J, Huang G, Chen J, Shi J, Xia J.
    Biomed Pharmacother; 2018 Jul 01; 103():1092-1100. PubMed ID: 29710674
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8. MiR-30a inhibits osteolysis by targeting RunX2 in giant cell tumor of bone.
    Huang Q, Jiang Z, Meng T, Yin H, Wang J, Wan W, Cheng M, Yan W, Liu T, Song D, Chen H, Wu Z, Xu W, Li Z, Zhou W, Xiao J.
    Biochem Biophys Res Commun; 2014 Oct 10; 453(1):160-5. PubMed ID: 25264196
    [Abstract] [Full Text] [Related]

  • 9. MicroRNA-106b inhibits osteoclastogenesis and osteolysis by targeting RANKL in giant cell tumor of bone.
    Wang T, Yin H, Wang J, Li Z, Wei H, Liu Z, Wu Z, Yan W, Liu T, Song D, Yang X, Huang Q, Zhou W, Xiao J.
    Oncotarget; 2015 Aug 07; 6(22):18980-96. PubMed ID: 26053181
    [Abstract] [Full Text] [Related]

  • 10. MicroRNA expression profiles in metastatic and non-metastatic giant cell tumor of bone.
    Mosakhani N, Pazzaglia L, Benassi MS, Borze I, Quattrini I, Picci P, Knuutila S.
    Histol Histopathol; 2013 May 07; 28(5):671-8. PubMed ID: 23172052
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 14. Long noncoding RNA TTN-AS1 enhances the malignant characteristics of osteosarcoma by acting as a competing endogenous RNA on microRNA-376a thereby upregulating dickkopf-1.
    Li S, Liu F, Pei Y, Wang W, Zheng K, Zhang X.
    Aging (Albany NY); 2019 Sep 16; 11(18):7678-7693. PubMed ID: 31525734
    [Abstract] [Full Text] [Related]

  • 15.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. The role of the tumor suppressor RUNX3 in giant cell tumor of the bone.
    Han YX, Liang DY.
    Int J Oncol; 2012 Mar 16; 40(3):673-8. PubMed ID: 22076387
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.